Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 2
2019 2
2020 1
2021 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Interactions of anthropometric indices, rs9939609 FTO gene polymorphism and breast cancer: A case-control study.
Doaei S, Bourbour F, Rastgoo S, Akbari ME, Gholamalizadeh M, Hajipour A, Moslem A, Ghorat F, Badeli M, Bagheri SE, Alizadeh A, Mokhtari Z, Pishdad S, JavadiKooshesh S, Azizi Tabesh G, Montazeri F, Joola P, Rezaei S, Dorosti M, Mosavi Jarrahi SA. Doaei S, et al. Among authors: javadikooshesh s. J Cell Mol Med. 2021 Apr;25(7):3252-3257. doi: 10.1111/jcmm.16394. Epub 2021 Feb 25. J Cell Mol Med. 2021. PMID: 33634577 Free PMC article.
The association between FTO rs9939609 polymorphism and serum lipid profile in adult women.
Jalili V, Mokhtari Z, Rastgoo S, Hajipour A, Bourbour F, Gholamalizadeh M, Mosavi Jarrahi A, JavadiKooshesh S, Moslem A, Abdollahi M, Doaei S. Jalili V, et al. Among authors: javadikooshesh s. Diabetol Metab Syndr. 2021 Nov 20;13(1):138. doi: 10.1186/s13098-021-00754-0. Diabetol Metab Syndr. 2021. PMID: 34801066 Free PMC article.
IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer.
Yousefi H, Momeny M, Ghaffari SH, Parsanejad N, Poursheikhani A, Javadikooshesh S, Zarrinrad G, Esmaeili F, Alishahi Z, Sabourinejad Z, Sankanian G, Shamsaiegahkani S, Bashash D, Shahsavani N, Tavakkoly-Bazzaz J, Alimoghaddam K, Ghavamzadeh A. Yousefi H, et al. Among authors: javadikooshesh s. Tumori. 2019 Feb;105(1):84-91. doi: 10.1177/0300891618784790. Epub 2018 Jul 19. Tumori. 2019. PMID: 30021477
Does the rs9939609 FTO gene polymorphism affect fat percentage? A meta-analysis.
Gholamalizadeh M, Mirzaei Dahka S, Vahid F, Bourbour F, Badeli M, JavadiKooshesh S, Mosavi Jarrahi SA, Akbari ME, Azizi Tabesh G, Montazeri F, Hassanpour A, Doaei S. Gholamalizadeh M, et al. Among authors: javadikooshesh s. Arch Physiol Biochem. 2022 Dec;128(6):1421-1425. doi: 10.1080/13813455.2020.1773861. Epub 2020 Jun 23. Arch Physiol Biochem. 2022. PMID: 32574121
Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells.
Momeny M, Eyvani H, Barghi F, Ghaffari SH, Javadikooshesh S, Hassanvand Jamadi R, Esmaeili F, Alishahi Z, Zaghal A, Bashash D, Samani FS, Ghaffari P, Dehpour AR, Tavangar SM, Alimoghaddam K, Ghavamzadeh A. Momeny M, et al. Among authors: javadikooshesh s. Anticancer Drugs. 2018 Nov;29(10):1011-1020. doi: 10.1097/CAD.0000000000000681. Anticancer Drugs. 2018. PMID: 30096128
The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M, Esmaeili F, Hamzehlou S, Yousefi H, Javadikooshesh S, Vahdatirad V, Alishahi Z, Mousavipak SH, Bashash D, Dehpour AR, Tavangar SM, Tavakkoly-Bazzaz J, Haddad P, Kordbacheh F, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Momeny M, et al. Among authors: javadikooshesh s. Cell Oncol (Dordr). 2019 Aug;42(4):491-504. doi: 10.1007/s13402-019-00448-w. Epub 2019 Apr 25. Cell Oncol (Dordr). 2019. PMID: 31025257